Marsh & Mclennan Cos (MMP) Position Maintained by Vaughan David Investments Inc; Nektar Therapeutics (NKTR) Holder Bridger Management Lowered Its Stake by $12.87 Million

February 22, 2018 - By Clifton Ray

Roberto Mignone decreased its stake in Nektar Therapeutics (NKTR) by 19.08% based on its latest 2017Q3 regulatory filing with the SEC. Bridger Management Llc sold 536,431 shares as the company’s stock rose 44.66% with the market. The hedge fund run by Roberto Mignone held 2.27 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $54.59 million, down from 2.81 million at the end of the previous reported quarter. Bridger Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $13.87 billion market cap company. The stock increased 3.59% or $3 during the last trading session, reaching $86.45. About 2.03 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 41.52% since February 22, 2017 and is uptrending. It has outperformed by 24.82% the S&P500.

Vaughan David Investments Inc increased its stake in Marsh & Mclennan Cos (MMP) by 1307.52% based on its latest 2017Q3 regulatory filing with the SEC. Vaughan David Investments Inc bought 261,504 shares as the company’s stock declined 7.68% while stock markets rallied. The institutional investor held 281,504 shares of the natural gas distribution company at the end of 2017Q3, valued at $23.59 million, up from 20,000 at the end of the previous reported quarter. Vaughan David Investments Inc who had been investing in Marsh & Mclennan Cos for a number of months, seems to be bullish on the $14.92B market cap company. The stock decreased 0.97% or $0.64 during the last trading session, reaching $65.44. About 426,446 shares traded. Magellan Midstream Partners, L.P. (NYSE:MMP) has risen 3.55% since February 22, 2017 and is uptrending. It has underperformed by 13.15% the S&P500.




Bridger Management Llc, which manages about $3.11B and $1.67B US Long portfolio, upped its stake in Mgm Resorts International (NYSE:MGM) by 485,397 shares to 1.52 million shares, valued at $49.65M in 2017Q3, according to the filing. It also increased its holding in Aetna Inc New (NYSE:AET) by 41,691 shares in the quarter, for a total of 386,100 shares, and has risen its stake in Molina Healthcare Inc (NYSE:MOH).

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on March, 7. They expect $-0.35 earnings per share, down 25.00% or $0.07 from last year’s $-0.28 per share. After $0.37 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts -194.59% negative EPS growth.

Since September 6, 2017, it had 0 insider purchases, and 18 selling transactions for $25.90 million activity. Shares for $87,440 were sold by KUEBLER CHRISTOPHER A. $1.09 million worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Doberstein Stephen K. Gergel Ivan P. had sold 100,000 shares worth $2.41M. Hora Maninder sold $189,575 worth of stock. Shares for $211,082 were sold by Thomsen Jillian B. on Friday, February 16. $2.93M worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Labrucherie Gil M.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 21 analyst reports since August 6, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $35.0 target in Wednesday, November 8 report. Jefferies maintained Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, August 16 with “Buy” rating. Roth Capital maintained it with “Buy” rating and $3100 target in Thursday, July 20 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Canaccord Genuity on Thursday, November 9. The firm earned “Buy” rating on Monday, November 13 by Roth Capital. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Wednesday, October 18 by Jefferies. The rating was maintained by J.P. Morgan on Tuesday, July 18 with “Buy”. The rating was maintained by Roth Capital on Tuesday, May 30 with “Buy”. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Roth Capital on Monday, September 21. The company was maintained on Wednesday, January 10 by Canaccord Genuity.

Investors sentiment decreased to 1.4 in 2017 Q3. Its down 0.49, from 1.89 in 2017Q2. It fall, as 15 investors sold NKTR shares while 52 reduced holdings. 26 funds opened positions while 68 raised stakes. 148.76 million shares or 1.09% more from 147.16 million shares in 2017Q2 were reported. Tci Wealth Advsrs Incorporated holds 192 shares. Alliancebernstein Lp owns 231,237 shares. First Republic, a California-based fund reported 25,864 shares. Comerica Bancorporation holds 0.03% or 164,797 shares in its portfolio. Moreover, Hanson Mcclain has 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 755 shares. Gsa Capital Ptnrs Llp stated it has 0.1% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Fic Capital reported 85,556 shares. 46,763 are held by Shell Asset Mgmt. Guggenheim Capital Ltd Liability Corp holds 0.01% in Nektar Therapeutics (NASDAQ:NKTR) or 197,540 shares. Rhenman And Asset Mngmt has invested 2.65% in Nektar Therapeutics (NASDAQ:NKTR). Bridger Mngmt Ltd Liability Corporation owns 2.27M shares. Pictet Asset Mngmt stated it has 0% in Nektar Therapeutics (NASDAQ:NKTR). Deutsche Natl Bank Ag reported 1.27M shares stake. Ubs Asset Mngmt Americas holds 0.01% or 412,946 shares. Fincl Bank Of Mellon Corporation reported 0.01% stake.

Among 23 analysts covering Magellan Midstream Partners L.P. (NYSE:MMP), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Magellan Midstream Partners L.P. had 59 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Underperform” rating by Mizuho given on Monday, July 10. UBS downgraded Magellan Midstream Partners, L.P. (NYSE:MMP) rating on Friday, February 3. UBS has “Neutral” rating and $81 target. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, September 7. DA Davidson initiated Magellan Midstream Partners, L.P. (NYSE:MMP) on Monday, November 16 with “Buy” rating. The stock of Magellan Midstream Partners, L.P. (NYSE:MMP) has “Buy” rating given on Saturday, August 8 by Raymond James. The firm has “Neutral” rating by JP Morgan given on Monday, May 16. On Friday, April 29 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Monday, December 19 the stock rating was initiated by Ladenburg Thalmann with “Buy”. Ladenburg Thalmann initiated the shares of MMP in report on Wednesday, July 13 with “Buy” rating. Stifel Nicolaus maintained it with “Hold” rating and $7700 target in Wednesday, August 2 report.

Investors sentiment is 0.9 in 2017 Q3. Its the same as in 2017Q2. It is the same, as 42 investors sold MMP shares while 161 reduced holdings. only 40 funds opened positions while 142 raised stakes. 134.51 million shares or 2.12% more from 131.72 million shares in 2017Q2 were reported. Haverford Trust has invested 0.03% in Magellan Midstream Partners, L.P. (NYSE:MMP). Mckinley Capital Mngmt Lc Delaware owns 0.06% invested in Magellan Midstream Partners, L.P. (NYSE:MMP) for 18,953 shares. Weaver C Barksdale & Assocs Incorporated owns 19,454 shares for 1.54% of their portfolio. Regis Mgmt Com Limited Com reported 6,902 shares. Company Bancshares owns 5,817 shares or 0.01% of their US portfolio. Rothschild Investment Il reported 21,750 shares. Raymond James & Associate holds 850,439 shares or 0.12% of its portfolio. Ameriprise owns 119,568 shares. Signaturefd Limited Liability Corporation invested in 0.07% or 7,175 shares. Evergreen Capital Management Llc owns 0.32% invested in Magellan Midstream Partners, L.P. (NYSE:MMP) for 38,260 shares. Fairview Inv Mgmt Ltd Liability Corp holds 1.72% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP) for 384,835 shares. 3,286 are owned by Colony Gp Ltd Liability Company. Glob Endowment Ltd Partnership reported 38,850 shares. Asset Mgmt stated it has 0.17% in Magellan Midstream Partners, L.P. (NYSE:MMP). Cetera Advisor Net Ltd Liability Co invested 0.03% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP).

Vaughan David Investments Inc, which manages about $1.81 billion and $2.04B US Long portfolio, decreased its stake in Monsanto Co (NYSE:MET) by 362,468 shares to 20,186 shares, valued at $2.42M in 2017Q3, according to the filing. It also reduced its holding in Enterprise Products (NYSE:ENB) by 469,248 shares in the quarter, leaving it with 61,200 shares, and cut its stake in Travelers Companies Inc (TITXF).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: